LBT Innovations
16 Anster St
Adelaide SA 5000
www.lbtinnovations.com

APAS® INDEPENDENCE SHOWCASED AT HIGH PROFILE US PHARMACEUTICAL MICROBIOLOGY CONFERENCE

New performance data presented from AstraZeneca and Clever Culture Systems

Adelaide, Australia, 11 October 2024: Australian medical technology company LBT Innovations Limited (ASX: LBT) (**LBT** or the **Company**), a leader in microbiology automation using artificial intelligence, is pleased to announce the Company's APAS® Independence technology was presented at the Parenteral Drug Association's annual Pharmaceutical Microbiology conference (**PDA Micro** or the **conference**) held in Washington, DC, United States from 07 October to 09 October 2024. PDA Micro is among the most prestigious conferences in pharmaceutical microbiology, attended by over 400 delegates including representatives from the majority of major global pharmaceutical companies.

Highlights:

- **APAS® Independence showcased at high profile US pharmaceutical microbiology conference: PDA Micro 2024, Washington, DC**
- **New APAS® Independence scientific data released at conference, including first results from AstraZeneca's validation studies**
  - **American Pharmaceutical Review White Paper: Evolving Validation Strategies for AI-based colony detection using APAS® Independence**
  - **Poster Presentation: Application of a High Throughput Automated Colony Counting System Powered by AI to Environmental Monitoring**
  - **Poster Presentation: Environmental Monitoring: Developing tests to challenge artificial intelligence models for colony counting using the APAS® Independence**
- **APAS® Independence dinner symposium with keynote presentation from Phil Duncanson, Global QC Microbiology, AstraZeneca**

Brent Barnes, CEO & Managing Director said:

"PDA Micro is an important event for the Company. It is attended by decision makers from many of the major pharmaceutical companies worldwide, providing a fantastic opportunity for us to showcase our technology. With our scientific and data driven approach we are making steady progress in establishing ourselves as the benchmark for automated plate reading within pharmaceutical microbiology. The positive engagement we had on our Company booth has further strengthened our growing pipeline of sales opportunities."

APAS® Independence demonstrated at annual PDA Micro conference in Washington DC, United States

The PDA Micro conference, held annually in Washington, DC, United States, is an important pharmaceutical microbiology industry event, attracting high profile key opinion leaders from major pharmaceutical companies and regulators. This year's conference provided the Company an opportunity to meet and engage with new customers, potential industry partners and regulators.

During the conference, the Company showcased the APAS® Independence on its booth including a virtual demonstration, allowing delegates to visualise the key features of the technology. In addition, the Company launched new scientific publications during the conference, highlighting new data from the validation of the APAS® technology, including poster presentations from both Clever Culture Systems and AstraZeneca. On the final night of the conference, AstraZeneca presented to over 30 delegates sharing their experiences validating the technology.

Demonstrating the APAS® Independence at key events, such as PDA Micro, is an important part of the Company's commercialisation strategy targeting large pharmaceutical customers and contract drug manufacturers. PDA Micro attracts decision makers from global pharmaceutical companies offering an opportunity to raise awareness of the technology, demonstrate scientific thought leadership and generate new sales leads.

LBT Innovations
16 Anster St
Adelaide SA 5000
www.lbtinnovations.com

The Clever Culture Systems team during PDA Micro

New APAS® Independence scientific data presented during PDA Micro 2024

The Company used this year's conference as a platform to launch new scientific data focusing on the validation of the APAS® Independence for routine use in pharmaceutical environmental monitoring workflows. Pharmaceutical companies adhere to strict change control processes when adopting new technologies, requiring thorough validation to ensure performance is non-inferior to existing methods. The data presented includes initial findings from AstraZeneca's external validation studies and specific challenge testing developed by the Company to test critical features of the APAS® Independence. These publications add to a growing body of scientific evidence supporting the use of APAS® Independence as an automated microbiology method.

Full details of the presentations can be found on the Company's website:

- **American Pharmaceutical Review White Paper: Evolving Validation Strategies for AI-based colony detection using APAS® Independence**
  Vanessa Figueroa[1], Andrew Gravett[2], Karen Capper[2], Steven Giglio[3,4]
  1. VVF Science, United States, 2. New Modalities and Parenterals, Pharmaceutical Technology & Development, Operations, AstraZeneca, Macclesfield, UK, 3. Clever Culture Systems, Australia 4. LBT Innovations, Australia
  American Pharma Review White Paper
- **Poster Presentation: Application of a High Throughput Automated Colony Counting System Powered by AI to Environmental Monitoring**
  Andrew Gravett[1], Natalie Williams[2], Karen Capper[1], and Phil Duncanson[2]
  1. AstraZeneca, Pharmaceutical Technology & Development, AstraZeneca, 2. Global QC Microbiology
  AstraZeneca PDA Micro 2024 Poster Presentation
- **Poster Presentation: Environmental Monitoring: Developing tests to challenge artificial intelligence models for colony counting using the APAS® Independence**
  Steven Giglio Ph.D, Scientific Director, Clever Culture Systems
  Clever Culture Systems PDA Micro 2024 Poster Presentation

Approved for release by the LBT Board.

– ENDS –

LBT Innovations
16 Anster St
Adelaide SA 5000
www.lbtinnovations.com

About LBT Innovations

LBT Innovations (LBT) provides intelligent automation solutions to microbiology laboratories. Based in Adelaide, South Australia, the Company has developed a best-in-class technology, the Automated Plate Assessment System (APAS® Independence), using artificial intelligence and machine learning software to automate the imaging, analysis and interpretation of microbiology culture plates. The technology remains the only US FDA-cleared artificial intelligence technology for automated culture plate reading and is being commercialised through LBT's wholly owned subsidiary Clever Culture Systems AG (CCS). The product is currently being sold to microbiology laboratories in the pharmaceutical manufacturing sector for the reading of environmental monitoring culture plates and to clinical laboratories as an in vitro diagnostic for infectious diseases. Thermo Fisher Scientific, Inc is exclusive distributor of the APAS® Independence to clinical customers in the United States and selected countries in Europe.

INVESTOR ENQUIRIES

LBT Innovations
Brent Barnes Chief Executive Officer & Managing Director Tel: +61 8 8227 1555 E: info@lbtinnovations.com